8-K: Mangoceuticals Acquires Global Patent Portfolio for Preventive Care, Enters Nutraceutical Market

Mangoceuticals, Inc. has acquired a global patent portfolio for an oral solution aimed at preventing infections, marking its entry into the non-prescription nutraceutical market.

Summary

• Mangoceuticals, Inc. has acquired a global patent portfolio from Intramont Technologies, Inc. for $20 million.
• The portfolio includes patents related to the prevention of infections, such as the common cold, respiratory diseases, and orally transmitted diseases like HPV.
• The payment consists of 980,000 shares of 6% Series C Convertible Preferred Stock valued at $19.6 million and $400,000 in cash.
• The cash payments are scheduled over several months, with $200,000 due by June 30, 2024, $100,000 by August 31, 2024, and $100,000 by November 30, 2024.
• The company plans to develop oral applications such as dissolvable tablets, lozenges, toothpaste, and mouthwash using the acquired patents.
• Intramont has been granted a co-exclusive, non-transferable license to use the patents, with a 10% royalty on gross worldwide sales starting April 24, 2025.
• The Series C Preferred Stock has a face value of $20 per share and is convertible into common stock at $10 per share, initially a 2-for-1 conversion ratio.
• The company believes it has regained compliance with Nasdaq's minimum stockholders' equity requirement of $2.5 million and also meets the $5 million equity requirement for initial listing.
• Mangoceuticals is seeking a further 180-day extension from Nasdaq to comply with the minimum bid price requirement and may conduct a reverse stock split.

Sentiment

Score: 7

Explanation: The document is generally positive due to the strategic acquisition and potential market opportunities, but there are some concerns about Nasdaq compliance and potential dilution.

Positives

• The acquisition expands Mangoceuticals' product portfolio into the non-prescription nutraceutical market.
• The acquired technology has a broad application in oral health, including toothpaste, mouthwash, and dissolvable tablets.
• The company believes it has regained compliance with Nasdaq's minimum stockholders' equity requirement.
• The global toothpaste market is projected to reach $25.71 billion by 2030, indicating a significant growth opportunity.

Negatives

• The company is still out of compliance with Nasdaq's minimum bid price requirement.
• The company may need to conduct a reverse stock split to regain compliance with the minimum bid price requirement.
• The company has a significant number of outstanding warrants to purchase shares of common stock at $1.00 per share, which could cause dilution.

Risks

• The company's ability to commercialize the acquired patent portfolio is subject to risks and uncertainties.
• The company's ability to obtain regulatory approvals for its products is not guaranteed.
• The company faces competition from other companies in the oral health market.
• The company's financial performance is subject to various economic and market risks.
• The company is dependent on third parties to prescribe and compound its ED product.

Future Outlook

The company intends to utilize the patents by commencing research, development, clinical trial studies and efficacy testing on a variety of oral applications. The company anticipates evidencing compliance with the Nasdaq minimum stockholders equity rule as of the date of its next periodic report. The company intends to request a further 180 day extension from Nasdaq to obtain compliance with the minimum bid price requirement and plans to a reverse stock split during the extension period, if necessary.

Management Comments

• Jacob Cohen, Co-Founder and CEO of MangoRx, stated, 'We are thrilled to integrate this groundbreaking solution into our current portfolio of products, as this further signifies our entrance into non-prescription, or non-Rx, based products, which can be sold both via direct-to-consumer online or in retail locations.'
• Jim Intrater, CEO and Founder of Intramont Technologies, Inc., commented, 'MangoRxs expertise in sales and marketing are of great potential help to our desires to bring forth new consumer health products to the general public.'

Industry Context

The acquisition aligns with the growing demand for oral health products, as the global toothpaste market is projected to reach $25.71 billion by 2030. The World Health Organization reports that nearly 3.5 billion people suffer from oral diseases globally, underscoring the need for innovative preventive measures. This move positions Mangoceuticals to capitalize on the increasing consumer interest in preventive healthcare and nutraceutical products.

Comparison to Industry Standards

• The acquisition of a patent portfolio for $20 million is a significant investment for a company of Mangoceuticals' size, indicating a strategic move to diversify its product offerings.
• The 10% royalty rate on Intramont's sales is a standard arrangement in licensing agreements, providing Mangoceuticals with a recurring revenue stream.
• The use of convertible preferred stock as part of the payment is a common method for financing acquisitions, allowing the company to conserve cash while providing the seller with potential upside.
• The company's efforts to regain compliance with Nasdaq listing requirements are crucial for maintaining investor confidence and access to capital markets.
• The company's move into the nutraceutical space is similar to other companies that are expanding their product lines to include both prescription and non-prescription products.

Stakeholder Impact

• Shareholders may benefit from the company's expansion into the nutraceutical market and potential revenue growth.
• Employees may have new opportunities in research, development, and marketing of the new products.
• Customers may have access to innovative preventive care products.
• Suppliers may have new opportunities to provide ingredients and materials for the new products.
• Creditors may be impacted by the company's financial performance and ability to repay debts.

Next Steps

• Mangoceuticals will commence research, development, clinical trial studies and efficacy testing on a variety of oral applications.
• The company will seek a further 180-day extension from Nasdaq to comply with the minimum bid price requirement.
• The company may conduct a reverse stock split to regain compliance with the minimum bid price requirement.
• The company will evidence compliance with the Nasdaq minimum stockholders equity rule as of the date of its next periodic report.

Key Dates

Keywords

patent portfolio, oral health, preventive care, nutraceuticals, convertible preferred stock, Nasdaq compliance, infections, royalty, licensing, reverse stock split